Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell S Berman

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Cancer Control : Journal of the Moffitt Cancer Center|November 9, 2021
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival AnalysisAvani M Kolla, Gerardo A Vitiello, Erica B Friedman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvantSylvia Adams, David W O'Neill, Daisuke Nonaka, et al.
Annals of Surgical Oncology|November 22, 2024
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional CohortKelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, et al.
Annals of Surgical Oncology|December 11, 2024
ASO Visual Abstract: Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-Institutional CohortKelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Cancer|April 7, 2021
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, et al.
Annals of Surgery|February 7, 2022
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral CentersKristy K Broman, Tasha M Hughes, Brooke C Bredbeck, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Cancer Control : Journal of the Moffitt Cancer Center|November 9, 2021
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival AnalysisAvani M Kolla, Gerardo A Vitiello, Erica B Friedman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvantSylvia Adams, David W O'Neill, Daisuke Nonaka, et al.
Annals of Surgical Oncology|November 22, 2024
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional CohortKelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, et al.
Annals of Surgical Oncology|December 11, 2024
ASO Visual Abstract: Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-Institutional CohortKelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Cancer|April 7, 2021
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, et al.
Annals of Surgery|February 7, 2022
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral CentersKristy K Broman, Tasha M Hughes, Brooke C Bredbeck, et al.
Pageof 10